Medical expert of the article
New publications
Preparations
B-immunoferon 1b
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
The drug B-imunoferon 1b (international name - Interferon beta-1b, analogues - betaferon, betaseron, avoneks, infibeta, extavia, Ronbetal, etc.) is assigned to the pharmacotherapeutic group of antiviral drugs, immunostimulants, cytokines and immunomodulators. Its pharmacological action is provided by a synthetically modified (recombinant) human interferon beta-1b.
[1]
Indications B-immunoferon 1b
B-imunoferon 1b is used to treat relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. It is recommended for secondary progressive forms of multiple sclerosis with the presence of relapses or acute attacks. Can be prescribed at the first clinically isolated symptoms, diagnosed as the initial stage of multiple sclerosis, to prevent an increase in the degree of lesion.
The use of the drug in multiple sclerosis with a re-progressive course can reduce the rate of progression of the disease leading to disability.
Release form
The form of this drug is dry powder (lyophilizate) for the preparation of solution for injection; 1 vial contains 9600000 IU of recombinant interferon beta -1b. To the preparation is applied a solvent - a solution of sodium chloride of 0.54%.
[4]
Pharmacodynamics
B-imunoferon 1b is a modulator of cellular immunity, whose biological activity is determined by the fact that the non-glycosylated interferon beta-1b protein binds to the specific receptors of some human cells, which reduces their susceptibility and enhances decay.
There is an assumption that multiple sclerosis has a viral etiology. Getting into the body of people with immune disorders, the virus causes an inadequate response of their immune system. The immune system begins to produce antibodies that destroy the substance of the soft shell of nerve fibers - myelin. Pharmacodynamics B-imunoferon 1b is based on the fact that interferon beta-1b inhibits the production of gamma-interferon and activates the function of T-lymphocytes of peripheral blood - the main regulators of the immune response of the body. As a result, the negative effect of antibodies on myelin is weakened.
Stabilizing the state of the hemato-encephalic barrier, B-imunoferon 1b has an anti-inflammatory effect.
Pharmacokinetics
1-8 hours after the administration of B-imunoferon 1b in a dose of 16 million IU, its maximum level in the blood plasma is about 40 IU / ml. Absolute bioavailability of the drug is approximately 50%.
With subcutaneous injections, which are performed every other day, an increase in its level in the blood plasma is not observed. After the introduction of the first dose of the drug (8 million IU), the level of such gene products and markers, as neopterin, β 2-microglobulin and cytokine IL-10, significantly increases after 6-12 hours. The maximum content of interferon beta-1b in the blood plasma is observed at least after 40 hours, maximum at five days.
Dosing and administration
The standard single dose of B-imunoferon 1b is 8000000 IU of the prepared solution, which is administered subcutaneously - every other day. Injection solution is prepared immediately before manipulation, for which a solvent is introduced into the vial of powder - 1.2 ml of sodium chloride solution (without additional shaking the powder must dissolve completely).
The duration of treatment with this drug is determined by the doctor.
Use B-immunoferon 1b during pregnancy
The use of B-imunoferon 1b during pregnancy is contraindicated because of a lack of studies of its potential teratogenicity. When prescribing this drug, women of reproductive age should be informed of the potential risk of spontaneous abortion and the need for reliable contraception. It is not recommended to use B-imunoferon 1b in the treatment of patients under the age of 18 years.
Contraindications
Contraindications to the use of B-imunoferon 1b include hypersensitivity to natural or recombinant interferon beta-1b, as well as to human albumin, severe depression and attempted suicide (in anamnesis), epilepsy, pathology and dysfunction of the liver and kidneys, no effect from drug treatment.
[5]
Side effects B-immunoferon 1b
At the initial stage of treatment with the drug B-imunoferon 1b, the following side effects occur: headache, fever, chills, muscle hypertonia, increased sweating. At the injection site, soreness, redness and swelling, inflammation are noted; perhaps thinning of the subcutaneous tissue layer, and occasionally - the development of tissue necrosis.
In the course of further use of the drug, side effects of B-imunoferon 1b may affect the nervous system (dizziness, anxiety, nervousness, confusion, memory loss), and cause conjunctivitis, impaired vision and speech. From the side of the cardiovascular system, the negative effect is expressed in the form of cardiac arrhythmia and increased blood pressure; from the side and hemopoiesis and peripheral circulation - in the form of hemorrhage, lymphopenia, neutropenia and leukopenia; from the musculoskeletal system - in the form of myasthenia gravis, arthralgia, myalgia and convulsions of the lower limbs.
Also, gastrointestinal reactions may occur in the form of diarrhea, constipation and vomiting. Possible violations of the menstrual cycle in women during menopause.
Patients with heart disease or increased activity of hepatic enzymes B-imunoferon 1b should be administered with caution and constant monitoring of the condition. In addition, this drug affects the ability to drive vehicles or work with mechanisms.
[6]
Interactions with other drugs
The interaction of B-imunoferon 1b with other drugs, in particular with other immunosuppressants, has not been sufficiently studied to date. However, this drug does not reduce the effectiveness of hormonal drugs used in the therapy of multiple sclerosis.
When treating exacerbations of the disease, care must be taken when prescribing drugs that affect hemocytopoiesis (hematopoiesis process).
In addition, B-imunoferon 1b requires caution in the simultaneous use of drugs whose metabolism is dependent on hepatic enzymes (cytochrome P450 system). These drugs include some antidepressants, as well as drugs for the treatment of epilepsy.
Storage conditions
The drug B-imunoferon 1b should be stored in the refrigerator (in the original packaging) at + 2-8 ° C.
Attention!
To simplify the perception of information, this instruction for use of the drug "B-immunoferon 1b" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.